cytokine release syndrome of new coronavirus pneumonia (COVID-19)
Conditions
Interventions
Case series:conventional therapy+tocilizumab
Sponsors
Central South Hospital of Wuhan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients volunteered to sign the informed consent; 2. Patients who were diagnosed with the common type of NCP and severe cases of new coronavirus pneumonia, Referring to the New Coronavirus Pneumonia Diagnosis and Treatment Plan, with elevation of IL-6, and grade 2-3 CRS.In the case of atypical signs of CRS, he or she should be judged by the investigator; 3. Aged >=18 years.
Exclusion criteria
Exclusion criteria: 1. People with serious or uncontrolled concomitant diseases, including sensory, vascular, heart, liver, kidney, gastric, intestinal, endocrine, etc.; 2. Having received Vaccine in the 4 weeks before entry or Planning to receive vaccine during the study; 3. Hypersensitivity to tocilizumab; 4. Pregnant or positive of the pregnancy test, lactating women; 5. Other reasons to exclude from the study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| including AE, SAE, laboratory findings, symptoms, vital signs, ECG, Physical examination.;The time to relive;The recurrence of CRS;The change of IL-1, IL-6, IFN-gama, TNF-alpha; | — |
Primary
| Measure | Time frame |
|---|---|
| the relive of CRS; | — |
Countries
china
Contacts
Public ContactZhiyong Peng
Central South Hospital, Wuhan University
Outcome results
None listed